Scientists probe Liver's power plants in fatty liver disease
NCT ID NCT05305287
Summary
This study aims to understand how the diabetes drug pioglitazone affects energy production inside liver cells in people with Type 2 diabetes and fatty liver disease (NAFLD or NASH). Researchers will measure chemical processes in the liver before and after 16 weeks of treatment. The goal is to gather detailed biological knowledge about how the drug works, which may inform future treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Diabetes Institute - University Health System
RECRUITINGSan Antonio, Texas, 78207, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Health Science Center at San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.